RBC Capital Maintains Outperform on DexCom, Lowers Price Target to $120
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh maintains an Outperform rating on DexCom (NASDAQ:DXCM) but lowers the price target from $130 to $120.
October 08, 2024 | 6:38 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital continues to see potential in DexCom with an Outperform rating, but has adjusted the price target down to $120 from $130, indicating a more cautious outlook.
The Outperform rating suggests continued confidence in DexCom's performance, but the lowered price target reflects a more cautious stance on its short-term valuation. This mixed signal may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100